عفونت HTLV-1 در زنان باردار و پیامدهای مادری و نوزادی آن: یک مطالعه مروری

نوع مقاله : مروری

نویسندگان

1 استادیار گروه علوم پایه، دانشکده علوم پزشکی اسفراین، اسفراین، ایران.

2 کارشناس ارشد مامایی، واحد توسعه تحقیقات بالینی، مرکز آموزشی، پژوهشی و درمانی امام خمینی (ره)، دانشکده علوم پزشکی اسفراین، اسفراین، ایران.

10.22038/ijogi.2024.79873.6088

چکیده

مقدمه: مادران باردار مبتلا به HTLV-1 اغلب بدون علامت هستند. انتقال از مادر به کودک عمدتاً از طریق شیردهی رخ می­دهد. مطالعه حاضر با هدف شناخت دقیق HTLV-1 در زنان باردار و پیامدهای مادری و نوزادی آن انجام شد.
روش‌کار: در این مطالعه مرور سیستماتیک، 126 مقاله انگلیسی با موضوع عفونت HTLV-1 در زنان باردار و نوزادان تا ماه مارس سال 2024، از طریق پایگاه‌های اطلاعاتی علمیSID ،Magiran ،PubMed ،Scopus ،Google Scholar و web of science با استفاده از کلمات کلیدی جستجو شدند. در نهایت 10 مقاله بر اساس معیارهای ورود شامل: مقالات با گزارش، تشخیص و درمان عفونت HTLV-1 در زنان باردار و مقالات با گزارش اثرات HTLV-1 بر روی جنین و نوزادان، تشخیص و درمان عفونت HTLV-1 در نوزادان انتخاب شد.
یافته­ ها: در بررسی انجام شده، اکثر زنان مبتلا به HTLV-1 در بارداری بدون علامت بودند. با وجود گزارش­ های موردی سقط، زایمان زودرس، محدودیت رشد داخل رحمی، مرده‌زایی، مرگ نوزاد ثانویه به پنومونی و هیدروسفالی مادرزادی، در مطالعات مقایسه ­ای بزرگ تفاوت معناداری در بروز پیامدهای نامطلوب بین دو گروه زنان سالم و مبتلا وجود نداشت (05/0p›). به‌نظر می ­رسد بقای مادر بعد از زایمان به شدت تحت تأثیر بیماری­ های ناشی از HTLV-1 به‌ویژه لوسمی سلول T بالغ (ATL) می­ باشد. میزان بالای مرگ‌و‌میر بالای مادران باردار مبتلا به ATL بعد از زایمان گزارش شده است.
نتیجه­ گیری: با توجه به میزان بالای مرگ‌و‌میر بالای مادران باردار مبتلا به ATL بعد از زایمان، پایش دقیق سلامت زنان مبتلا به ATL منطقی به‌نظر می رسد. تدوین پروتکل جهت کاهش انتقال عمودی عفونت در مناطق اندمیک توصیه می­ شود.

کلیدواژه‌ها

موضوعات

عنوان مقاله [English]

HTLV-1 infection in pregnant women and its maternal and neonatal outcomes: a review study

نویسندگان [English]

  • Bagher Moradi 1
  • Ashraf Saber 2
1 Assistant Professor, Department of Basic Sciences, Esfarayen Faculty of Medical Sciences, Esfarayen, Iran.
2 M.Sc. of Midwifery, Clinical Research Development Unit, Imam Khomeini Education, Research and Treatment Center, Esfarayen Faculty of Medical Sciences, Esfarayen, Iran.
چکیده [English]

Introduction: Pregnant women with HTLV-1 are mostly asymptomatic. Mother-to-child transmission mainly occur through breastfeeding. The present study was carried out with aim to identify HTLV-1 in pregnant women and its adverse maternal and neonatal outcome.
Methods: In this systematic review, 126 English articles on the topic of HTLV-1 infection in pregnant women and newborns were searched through SID, Magiran, PubMed, Scopus, Google Scholar, and web of science databases using keywords until March 2024. Finally, 10 articles based on the inclusion criteria including: articles with reporting, diagnosis and treatment of HTLV-1 infection in pregnant women and articles reporting the effects of HTLV-1 on fetuses and infants, diagnosis and treatment of HTLV-1 infection in infants were selected.
Results: In the review, most of the pregnant women infected with HTLV-1 were asymptomatic. Despite the case reports of abortion, premature birth, intrauterine growth restriction, stillbirth, infant death secondary to pneumonia and congenital hydrocephalus, in large comparative studies, there was no significant difference in the incidence of adverse outcomes between the two groups of healthy and affected women (P>0.05). It seems that mother's survival after delivery is strongly affected by diseases caused by HTLV-1, especially Adult T-cell leukemia (ATL). A high mortality rate among pregnant mothers with ATL after delivery has been reported.
Conclusion: Considering the high mortality rate of pregnant mothers with ATL after delivery, careful monitoring of the health of women with ATL seems reasonable. It is recommended to develop a protocol to reduce the vertical transmission of infection in endemic areas.

کلیدواژه‌ها [English]

  • HTlV-1
  • Newborn
  •  Pregnancy outcome
  • Pregnant women

مراجع

  1. Marino-Merlo F, Balestrieri E, Matteucci C, Mastino A, Grelli S, Macchi B. Antiretroviral therapy in HTLV-1 infection: an updated overview. Pathogens 2020; 9(5):342.
  2. Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Frontiers in microbiology 2012; 3:388.
  3. Tagaya Y, Matsuoka M, Gallo R. 40 years of the human T-cell leukemia virus: past, present, and future. F1000Research 2019; 8.
  4. Nozuma S, Yoshimura A, Pai SC, Chen HJ, Matsuura E, Tanaka M, et al. Geographic characteristics of HTLV-1 molecular subgroups and genetic substitutions in East Asia: Insights from complete genome sequencing of HTLV-1 strains isolated in Taiwan and Japan. PLOS Neglected Tropical Diseases 2024; 18(2):e0011928.
  5. Encinas B, Benito R, Rojo S, Reina G, Montiel N, Aguilera A, et al. Human T-lymphotropic virus-1 infection among Latin American pregnant women living in Spain. IJID regions 2024; 10:146-9.
  6. Forlani G, Shallak M, Accolla RS, Romanelli MG. HTLV-1 infection and pathogenesis: new insights from cellular and animal models. International Journal of Molecular Sciences 2021; 22(15):8001.
  7. Miyazawa T, Hasebe Y, Murase M, Sakurai M, Itabashi K, Yonemoto N. The effect of early postnatal nutrition on human T cell leukemia virus type 1 mother-to-child transmission: A systematic review and meta-analysis. Viruses 2021; 13(5):819.
  8. Bangham CR, Ratner L. How does HTLV-1 cause adult T-cell leukaemia/lymphoma (ATL)?. Current opinion in virology 2015; 14:93-100.
  9. Dugardin J, Demar M, Hafsi N, Amroun H, Aurelus JM, Drak Alsibai K, et al. Human T-cell leukemia virus type 1 is associated with dysthyroidism in the French Amazon. Frontiers in Cellular and Infection Microbiology 2023; 13:1164526.
  10. Bohiltea RE, Turcan N, Berceanu C, Munteanu O, Georgescu TA, Ducu I, et al. Implications of human T‑lymphotropic virus in pregnancy: A case report and a review of the diagnostic criteria and management proposal. Experimental and Therapeutic Medicine 2021; 21(1):1-.
  11. Itabashi K, Miyazawa T. Mother-to-child transmission of human T-cell leukemia virus type 1: mechanisms and nutritional strategies for prevention. Cancers 2021; 13(16):4100.
  12. Soriano V, de Mendoza C, Network SH. Screening for HTLV-1 infection should be expanded in Europe. International Journal of Infectious Diseases 2024; 140:99-101.
  13. Sodré Barmpas DB, Monteiro DL, Taquette SR, Rodrigues NC, Trajano AJ, Cunha JD, et al. Pregnancy outcomes and mother-to-child transmission rate in HTLV-1/2 infected women attending two public hospitals in the metropolitan area of Rio de Janeiro. PLOS neglected tropical diseases 2019; 13(6):e0007404.
  14. Mohanty S, Harhaj EW. Mechanisms of oncogenesis by HTLV-1 Tax. Pathogens 2020; 9(7):543.
  15. Brites C, Grassi MF, Quaresma JA, Ishak R, Vallinoto AC. Pathogenesis of HTLV-1 infection and progression biomarkers: An overview. Brazilian Journal of Infectious Diseases 2021; 25:101594.
  16. Martin F, Tagaya Y, Gallo R. Time to eradicate HTLV-1: an open letter to WHO. The Lancet 2018; 391(10133):1893-4.
  17. Eusebio-Ponce E, Anguita E, Paulino-Ramirez R, Candel FJ. HTLV-1 infection: An emerging risk. Pathogenesis, epidemiology, diagnosis and associated diseases. Revista Española de Quimioterapia 2019; 32(6):485.
  18. Percher F, Jeannin P, Martin-Latil S, Gessain A, Afonso PV, Vidy-Roche A, et al. Mother-to-child transmission of HTLV-1 epidemiological aspects, mechanisms and determinants of mother-to-child transmission. Viruses 2016; 8(2):40.
  19. Fujino T, Fujiyoshi T, Yashiki S, Sonoda S, Otsuka H, Nagata Y. HTLV-I transmission from mother to fetus via placenta. Lancet 1992; 340(8828):1157.
  20. Bittencourt AL, Sabino EC, Costa MC, Pedroso C, Moreira L. No evidence of vertical transmission of HTLV-I in bottle-fed children. Revista do Instituto de Medicina Tropical de São Paulo 2002; 44:63-5.
  21. Sawada T, Taguchi H, Miyoshi I, Nakachi H, Nagayama T. HTLV-1 proviral DNA in oral aspirates of newborns born to seropositive mothers. JAMA 1995; 273(4):284.
  22. Yamamoto T, Terada K, Nishida N, Moriuchi R, Shirabe S, Nakamura T, et al. Inhibitory activity in saliva of cell-to-cell transmission of human T-cell lymphotropic virus type 1 in vitro: evaluation of saliva as an alternative source of transmission. Journal of clinical microbiology 1995; 33(6):1510-5.
  23. Rosadas C, Malik B, Taylor GP, Puccioni-Sohler M. Estimation of HTLV-1 vertical transmission cases in Brazil per annum. PLoS neglected tropical diseases 2018; 12(11):e0006913.
  24. Hamedi A, Akhlaghi F, Meshkat Z, Sezavar M, Nomani H, Meshkat M. The prevalence of human T‐Cell lymphotropic virus Type 1 in pregnant women and their newborns. International Scholarly Research Notices 2012; 2012(1):975135.
  25. Rosadas C, Tosswill JH, Tedder R, Taylor GP. Pregnancy does not adversely impact diagnostic tests for HTLV-1/2 infection. PLoS neglected tropical diseases 2019; 13(9):e0007736.
  26. Bittencourt AL. Vertical transmission of HTLV-I/II: a review. Revista do Instituto de Medicina Tropical de São Paulo 1998; 40:245-51.
  27. Cook LB, Elemans M, Rowan AG, Asquith B. HTLV-1: persistence and pathogenesis. Virology 2013; 435(1):131-40.
  28. Vieira BA, Bidinotto AB, Dartora WJ, Pedrotti LG, de Oliveira VM, Wendland EM. Prevalence of human T-lymphotropic virus type 1 and 2 (HTLV-1/-2) infection in pregnant women in Brazil: a systematic review and meta-analysis. Scientific reports 2021; 11(1):15367.
  29. Tezuka K, Fuchi N, Okuma K, Tsukiyama T, Miura S, Hasegawa Y, et al. HTLV-1 targets human placental trophoblasts in seropositive pregnant women. The journal of clinical investigation 2020; 130(11):6171-86.
  30. Mahieux R. A vaccine against HTLV-1 HBZ makes sense. Blood, The Journal of the American Society of Hematology 2015; 126(9):1052-3.
  31. Schneiderman BS, Barski MS, Maertens GN. Cabotegravir, the Long-Acting Integrase Strand Transfer Inhibitor, Potently Inhibits Human T-Cell Lymphotropic Virus Type 1 Transmission in vitro. Frontiers in Medicine 2022; 9:889621.
  32. Itabashi K, Miyazawa T, Sekizawa A, Tokita A, Saito S, Moriuchi H, et al. A nationwide antenatal human T-cell leukemia virus type-1 antibody screening in Japan. Frontiers in Microbiology 2020; 11:595.
  33. Barr RS, Drysdale SB, Boullier M, Lyall H, Cook L, Collins GP, et al. A Review of the prevention of mother-to-child transmission of human T-Cell lymphotrophic virus type 1 (HTLV-1) with a proposed management algorithm. Frontiers in Medicine 2022; 9:941647.
  34. Komatsu N, Iwanaga M, Hasegawa Y, Miura S, Fuchi N, Moriuchi H, et al. Frequency of HTLV-1 seroconversion between pregnancies in Nagasaki, Japan, 2011–2018. Frontiers in Microbiology 2022; 13:1036955.
  35. Amor MM, Olaso AS, Atienza R, Stueben B, Cohen S, Kossev P. Adult T‐cell leukemia‐lymphoma during pregnancy. Case Reports in Oncological Medicine 2013; 2013(1):631825.
  36. Safdar A, Johnson N, Gonzalez F, Busowski JD. Adult T-cell leukemia–lymphoma during pregnancy. New England Journal of Medicine 2002; 346(25):2014-5.
  37. Ville Y, Delaporte E, Peeters M, Leruez M, Glowaczower E, Fernandez H. Human T-cell lymphotropic virus type I infection and pregnancy: a case-control study and 12-month follow-up of 135 women and their infants. American journal of obstetrics and gynecology 1991; 165(5):1438-43.
  38. Tamaki Y, Higa F, Tasato D, Nakamura H, Uechi K, Tamayose M, et al. Pneumocystis jirovecii pneumonia and alveolar hemorrhage in a pregnant woman with human T cell lymphotropic virus type-1 infection. Internal Medicine 2011; 50(4):351-4.
  39. Mori H, Shibata E, Kuwazuru T, Uchimura T, Kondo E, Iwanaka Y, et al. Pregnancy complicated by HTLV‐1‐associated myelopathy/tropical spastic paraparesis (HAM/TSP): a case report. Clinical case reports 2021; 9(7):e04511.
  40. Bittencourt AL, Dourado I, Bastos Filho P, Santos M, Valadão E, Carlos L, et al. Human T-cell lymphotropic virus type 1 infection among pregnant women in northeastern Brazil. JAIDS Journal of Acquired Immune Deficiency Syndromes 2001; 26(5):490-4.
  41. Motedayen Aval L, Boullier M, Lyall H, Collins GP, Ayto R, Kelly DF, et al. Adult T cell leukaemia/lymphoma (ATL) in pregnancy: A UK case series. EJHaem 2021; 2(1):131-5.
  42. Dal FM, da Cunha RV, Bóia MN, Portela P, Botelho CA, de Freitas GM, et al. HTLV 1/2 infection: prenatal performance as a disease control strategy in State of Mato Grosso do Sul. Revista da Sociedade Brasileira de Medicina Tropical 2008; 41(2).
  43. Alarcón JO, Friedman HB, Montano SM, Zunt JR, Holmes KK, Quinnan Jr GV. High endemicity of human T-cell lymphotropic virus type 1 among pregnant women in Peru. JAIDS Journal of Acquired Immune Deficiency Syndromes 2006; 42(5):604-9.
  44. Kubota R, Kawanishi T, Matsubara H, Manns A, Jacobson S. Demonstration of human T lymphotropic virus type I (HTLV-I) tax-specific CD8+ lymphocytes directly in peripheral blood of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by intracellular cytokine detection. The Journal of Immunology 1998; 161(1):482-8.
  45. Tohyama J, Kawahara H, Inagaki M, Ohno K, Takeshita K, Egi T. Clinical and neuroradiologic findings of congenital hydrocephalus in infant born to mother with HTLV‐I‐associated myelopathy. Neurology 1992; 42(7):1406.
  46. Cook LB, Phillips AA. How I treat adult T-cell leukemia/lymphoma. Blood, The Journal of the American Society of Hematology 2021; 137(4):459-70.
  47. Bazarbachi A, Suarez F, Fields P, Hermine O. How I treat adult T-cell leukemia/lymphoma. Blood, the Journal of the American Society of Hematology 2011; 118(7):1736-45.
مجله زنان، مامایی و نازایی ایران
دوره 27، شماره 6
شهریور 1403
صفحه 55-67

فایل ها

هم رسانی

ارجاع به این مقاله

آمار